<DOC>
	<DOCNO>NCT00005619</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure detect residual disease may predict disease relapse patient hairy cell leukemia . PURPOSE : Diagnostic trial determine effectiveness analyze blood bone marrow detect residual disease patient previously treat hairy cell leukemia .</brief_summary>
	<brief_title>Analysis Blood Bone Marrow Detect Residual Disease Patients With Previously Treated Hairy Cell Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Compare sensitivity flow cytometry , immunohistochemistry , polymerase chain reaction detect minimal residual disease follow therapy cladribine patient hairy cell leukemia . OUTLINE : Blood bone marrow sample obtain patient time bone marrow biopsy assess minimal residual disease use flow cytometry , immunohistochemistry , polymerase chain reaction . Patients follow 2 year disease relapse . PROJECTED ACCRUAL : A total 15 patient accrue study 12-24 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Clinically document hairy cell leukemia Active remission Must receive prior cladribine undergo bone marrow biopsy follow PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior chemotherapy follow prior cladribine Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>progressive hairy cell leukemia , initial treatment</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
</DOC>